ADIL (Adial Pharmaceuticals) Other Current Liabilities: $1.46 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADIL Adial Pharmaceuticals Inc ADIL
30 GF Score
Price $5.94
! 1 Warning Sign
View Full Analysis

What is Adial Pharmaceuticals Other Current Liabilities?

Adial Pharmaceuticals ADIL +2.59% 30 Other Current Liabilities is $1.46 Mil as of Jun. 2026. GuruFocus rates ADIL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Adial Pharmaceuticals's other current liabilities for the quarter that ended in Jun. 2026 was $1.46 Mil.

Adial Pharmaceuticals's quarterly other current liabilities increased from Dec. 2025 ($0.66 Mil) to Mar. 2026 ($0.84 Mil) and increased from Mar. 2026 ($0.84 Mil) to Jun. 2026 ($1.46 Mil).

Adial Pharmaceuticals's annual other current liabilities declined from Dec. 2023 ($0.42 Mil) to Dec. 2024 ($0.41 Mil) but then increased from Dec. 2024 ($0.41 Mil) to Dec. 2025 ($0.66 Mil).

Adial Pharmaceuticals Other Current Liabilities Related Terms

Adial Pharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Adial Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adial Pharmaceuticals Other Current Liabilities Chart

Adial Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 1.14 0.42 0.41 0.66

Adial Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.51 0.66 0.84 1.46
ADIL
30GF Score
Adial Pharmaceuticals Inc ADIL
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adial Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.46 Mil mean?
Adial Pharmaceuticals (ADIL) has a Other Current Liabilities of $1.46 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adial Pharmaceuticals.
Is Adial Pharmaceuticals' Other Current Liabilities too high?
Adial Pharmaceuticals' current Other Current Liabilities is $1.46 Mil. Overall, Adial Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Adial Pharmaceuticals' Other Current Liabilities compare to PULM and KAPA?
Adial Pharmaceuticals' Other Current Liabilities of $1.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Adial Pharmaceuticals. Adial Pharmaceuticals's current Other Current Liabilities is $1.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adial Pharmaceuticals stock overvalued right now?
Adial Pharmaceuticals (ADIL) has a current Other Current Liabilities of $1.46 Mil. The current Other Current Liabilities is $1.46 Mil. Adial Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Adial Pharmaceuticals (ADIL), the current Other Current Liabilities is $1.46 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adial Pharmaceuticals Business Description

Address 4870 Sadler Road, Suite 300, Glen Allen, VA, USA, 23060
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
30GF Score

Get the complete analysis for ADIL

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.94
Price